LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy (trastuzumab), cancer stem cell (CSC)-like properties and multiple chemoresistance often concur and intersect in breast cancer, but molecular links that may serve as effective therapeutic targets remain largely unknown. H...

Full description

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2022-10, Vol.8 (1), p.115-115, Article 115
Main Authors: Bai, Wendong, Peng, Hongyan, Zhang, Jiarui, Zhao, Yongmei, Li, Zhijun, Feng, Xuelian, Zhang, Jiang, Liang, Fei, Wang, Li, Zhang, Nan, Li, Yize, Zhu, Huayu, Ji, Qiuhe
Format: Article
Language:English
Subjects:
631/337/384
692/4028/67/1059/2326
692/53/2422
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Biopsy
Breast cancer
Cancer Research
Cell Biology
Cloning
Drug resistance
Epidermal growth factor
Human Genetics
Liver cancer
Lymphatic system
Medical prognosis
Medical research
Oncology
Patients
Proteins
Roles
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073
cites cdi_FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073
container_end_page 115
container_issue 1
container_start_page 115
container_title NPJ breast cancer
container_volume 8
creator Bai, Wendong
Peng, Hongyan
Zhang, Jiarui
Zhao, Yongmei
Li, Zhijun
Feng, Xuelian
Zhang, Jiang
Liang, Fei
Wang, Li
Zhang, Nan
Li, Yize
Zhu, Huayu
Ji, Qiuhe
description Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy (trastuzumab), cancer stem cell (CSC)-like properties and multiple chemoresistance often concur and intersect in breast cancer, but molecular links that may serve as effective therapeutic targets remain largely unknown. Here, we identified the long noncoding RNA, LINC00589 as a key regulatory node for concurrent intervention of these processes in breast cancer cells in vitro and in vivo. We demonstrated that the expression of LINC00589 is clinically valuable as an independent prognostic factor for discriminating trastuzumab responders. Mechanistically, LINC00589 serves as a ceRNA platform that simultaneously sponges miR-100 and miR-452 and relieves their repression of tumor suppressors, including discs large homolog 5 ( DLG5 ) and PR/SET domain 16 ( PRDM16 , a transcription suppressor of mucin4 ), thereby exerting multiple cancer inhibitory functions and counteracting drug resistance. Collectively, our results disclose two LINC00589 -initiated ceRNA networks, the LINC00589 - miR-100 - DLG5 and LINC00589 - miR-452 - PRDM16 - mucin4 axes, which regulate trastuzumab resistance, CSC-like properties and multiple chemoresistance of breast cancer, thus providing potential diagnostic and prognostic markers and therapeutic targets for HER2-positive breast cancer.
doi_str_mv 10.1038/s41523-022-00484-0
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cd232e58e9a24f2eb973d30f7c78ab61</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cd232e58e9a24f2eb973d30f7c78ab61</doaj_id><sourcerecordid>2730316926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073</originalsourceid><addsrcrecordid>eNp9kk9r3DAQxU1paUKaL9CToJdCcTv6Y0u6FMKSNAtLCiF3IcnjjTe2tZXslt760aONl7bpobpIzLz30zC8onhL4SMFrj4lQSvGS2CsBBBKlPCiOGVcilLUUr78631SnKe0AwAqaqUr-ro44TUHXQE_LX5t1jcrgErpsglDN9oJG-Lx9uaCjDj9CPEhkYjbuc8NMsz91O17JP4ehxAxdWmyo0dix2w6vCJJEw4Z0Pdl3z0g2cewxzh1mEg3kuvLW_aBuIg2TUfDm-JVa_uE58f7rLi7urxbXZebr1_Wq4tN6Ssqp7JpOAdaeWcdYyqXKApea41aOUcby6h1tXRSUe8r4SQwL1onHKOUOpD8rFgv2CbYndnHbrDxpwm2M0-FELfG5jF9j8Y3jDOsFGrLRMvQackbDq30UuVPaGZ9Xlj72Q3YeBynaPtn0Oedsbs32_Dd6JpKpXQGvD8CYvg2Y5rM0KXDzuyIYU6GSQ6c1prVWfruH-kuzHHMm8oqpg8Hqqxii8rHkFLE9vcwFMwhLmaJi8lxMU9xMZBNfDGlLB63GP-g_-N6BHrGwRA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729999905</pqid></control><display><type>article</type><title>LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer</title><source>PubMed Central Free</source><source>Publicly Available Content Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Bai, Wendong ; Peng, Hongyan ; Zhang, Jiarui ; Zhao, Yongmei ; Li, Zhijun ; Feng, Xuelian ; Zhang, Jiang ; Liang, Fei ; Wang, Li ; Zhang, Nan ; Li, Yize ; Zhu, Huayu ; Ji, Qiuhe</creator><creatorcontrib>Bai, Wendong ; Peng, Hongyan ; Zhang, Jiarui ; Zhao, Yongmei ; Li, Zhijun ; Feng, Xuelian ; Zhang, Jiang ; Liang, Fei ; Wang, Li ; Zhang, Nan ; Li, Yize ; Zhu, Huayu ; Ji, Qiuhe</creatorcontrib><description>Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy (trastuzumab), cancer stem cell (CSC)-like properties and multiple chemoresistance often concur and intersect in breast cancer, but molecular links that may serve as effective therapeutic targets remain largely unknown. Here, we identified the long noncoding RNA, LINC00589 as a key regulatory node for concurrent intervention of these processes in breast cancer cells in vitro and in vivo. We demonstrated that the expression of LINC00589 is clinically valuable as an independent prognostic factor for discriminating trastuzumab responders. Mechanistically, LINC00589 serves as a ceRNA platform that simultaneously sponges miR-100 and miR-452 and relieves their repression of tumor suppressors, including discs large homolog 5 ( DLG5 ) and PR/SET domain 16 ( PRDM16 , a transcription suppressor of mucin4 ), thereby exerting multiple cancer inhibitory functions and counteracting drug resistance. Collectively, our results disclose two LINC00589 -initiated ceRNA networks, the LINC00589 - miR-100 - DLG5 and LINC00589 - miR-452 - PRDM16 - mucin4 axes, which regulate trastuzumab resistance, CSC-like properties and multiple chemoresistance of breast cancer, thus providing potential diagnostic and prognostic markers and therapeutic targets for HER2-positive breast cancer.</description><identifier>ISSN: 2374-4677</identifier><identifier>EISSN: 2374-4677</identifier><identifier>DOI: 10.1038/s41523-022-00484-0</identifier><identifier>PMID: 36309503</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/337/384 ; 692/4028/67/1059/2326 ; 692/53/2422 ; 692/699/67/1347 ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Breast cancer ; Cancer Research ; Cell Biology ; Cloning ; Drug resistance ; Epidermal growth factor ; Human Genetics ; Liver cancer ; Lymphatic system ; Medical prognosis ; Medical research ; Oncology ; Patients ; Proteins ; Roles ; Stem cells</subject><ispartof>NPJ breast cancer, 2022-10, Vol.8 (1), p.115-115, Article 115</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073</citedby><cites>FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073</cites><orcidid>0000-0001-6137-2252 ; 0000-0002-3038-6624 ; 0000-0002-3010-5837</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2729999905/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2729999905?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Bai, Wendong</creatorcontrib><creatorcontrib>Peng, Hongyan</creatorcontrib><creatorcontrib>Zhang, Jiarui</creatorcontrib><creatorcontrib>Zhao, Yongmei</creatorcontrib><creatorcontrib>Li, Zhijun</creatorcontrib><creatorcontrib>Feng, Xuelian</creatorcontrib><creatorcontrib>Zhang, Jiang</creatorcontrib><creatorcontrib>Liang, Fei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Yize</creatorcontrib><creatorcontrib>Zhu, Huayu</creatorcontrib><creatorcontrib>Ji, Qiuhe</creatorcontrib><title>LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer</title><title>NPJ breast cancer</title><addtitle>npj Breast Cancer</addtitle><description>Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy (trastuzumab), cancer stem cell (CSC)-like properties and multiple chemoresistance often concur and intersect in breast cancer, but molecular links that may serve as effective therapeutic targets remain largely unknown. Here, we identified the long noncoding RNA, LINC00589 as a key regulatory node for concurrent intervention of these processes in breast cancer cells in vitro and in vivo. We demonstrated that the expression of LINC00589 is clinically valuable as an independent prognostic factor for discriminating trastuzumab responders. Mechanistically, LINC00589 serves as a ceRNA platform that simultaneously sponges miR-100 and miR-452 and relieves their repression of tumor suppressors, including discs large homolog 5 ( DLG5 ) and PR/SET domain 16 ( PRDM16 , a transcription suppressor of mucin4 ), thereby exerting multiple cancer inhibitory functions and counteracting drug resistance. Collectively, our results disclose two LINC00589 -initiated ceRNA networks, the LINC00589 - miR-100 - DLG5 and LINC00589 - miR-452 - PRDM16 - mucin4 axes, which regulate trastuzumab resistance, CSC-like properties and multiple chemoresistance of breast cancer, thus providing potential diagnostic and prognostic markers and therapeutic targets for HER2-positive breast cancer.</description><subject>631/337/384</subject><subject>692/4028/67/1059/2326</subject><subject>692/53/2422</subject><subject>692/699/67/1347</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Cancer Research</subject><subject>Cell Biology</subject><subject>Cloning</subject><subject>Drug resistance</subject><subject>Epidermal growth factor</subject><subject>Human Genetics</subject><subject>Liver cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Oncology</subject><subject>Patients</subject><subject>Proteins</subject><subject>Roles</subject><subject>Stem cells</subject><issn>2374-4677</issn><issn>2374-4677</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk9r3DAQxU1paUKaL9CToJdCcTv6Y0u6FMKSNAtLCiF3IcnjjTe2tZXslt760aONl7bpobpIzLz30zC8onhL4SMFrj4lQSvGS2CsBBBKlPCiOGVcilLUUr78631SnKe0AwAqaqUr-ro44TUHXQE_LX5t1jcrgErpsglDN9oJG-Lx9uaCjDj9CPEhkYjbuc8NMsz91O17JP4ehxAxdWmyo0dix2w6vCJJEw4Z0Pdl3z0g2cewxzh1mEg3kuvLW_aBuIg2TUfDm-JVa_uE58f7rLi7urxbXZebr1_Wq4tN6Ssqp7JpOAdaeWcdYyqXKApea41aOUcby6h1tXRSUe8r4SQwL1onHKOUOpD8rFgv2CbYndnHbrDxpwm2M0-FELfG5jF9j8Y3jDOsFGrLRMvQackbDq30UuVPaGZ9Xlj72Q3YeBynaPtn0Oedsbs32_Dd6JpKpXQGvD8CYvg2Y5rM0KXDzuyIYU6GSQ6c1prVWfruH-kuzHHMm8oqpg8Hqqxii8rHkFLE9vcwFMwhLmaJi8lxMU9xMZBNfDGlLB63GP-g_-N6BHrGwRA</recordid><startdate>20221029</startdate><enddate>20221029</enddate><creator>Bai, Wendong</creator><creator>Peng, Hongyan</creator><creator>Zhang, Jiarui</creator><creator>Zhao, Yongmei</creator><creator>Li, Zhijun</creator><creator>Feng, Xuelian</creator><creator>Zhang, Jiang</creator><creator>Liang, Fei</creator><creator>Wang, Li</creator><creator>Zhang, Nan</creator><creator>Li, Yize</creator><creator>Zhu, Huayu</creator><creator>Ji, Qiuhe</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6137-2252</orcidid><orcidid>https://orcid.org/0000-0002-3038-6624</orcidid><orcidid>https://orcid.org/0000-0002-3010-5837</orcidid></search><sort><creationdate>20221029</creationdate><title>LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer</title><author>Bai, Wendong ; Peng, Hongyan ; Zhang, Jiarui ; Zhao, Yongmei ; Li, Zhijun ; Feng, Xuelian ; Zhang, Jiang ; Liang, Fei ; Wang, Li ; Zhang, Nan ; Li, Yize ; Zhu, Huayu ; Ji, Qiuhe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/337/384</topic><topic>692/4028/67/1059/2326</topic><topic>692/53/2422</topic><topic>692/699/67/1347</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Cancer Research</topic><topic>Cell Biology</topic><topic>Cloning</topic><topic>Drug resistance</topic><topic>Epidermal growth factor</topic><topic>Human Genetics</topic><topic>Liver cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Oncology</topic><topic>Patients</topic><topic>Proteins</topic><topic>Roles</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Wendong</creatorcontrib><creatorcontrib>Peng, Hongyan</creatorcontrib><creatorcontrib>Zhang, Jiarui</creatorcontrib><creatorcontrib>Zhao, Yongmei</creatorcontrib><creatorcontrib>Li, Zhijun</creatorcontrib><creatorcontrib>Feng, Xuelian</creatorcontrib><creatorcontrib>Zhang, Jiang</creatorcontrib><creatorcontrib>Liang, Fei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Yize</creatorcontrib><creatorcontrib>Zhu, Huayu</creatorcontrib><creatorcontrib>Ji, Qiuhe</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Health and Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>NPJ breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Wendong</au><au>Peng, Hongyan</au><au>Zhang, Jiarui</au><au>Zhao, Yongmei</au><au>Li, Zhijun</au><au>Feng, Xuelian</au><au>Zhang, Jiang</au><au>Liang, Fei</au><au>Wang, Li</au><au>Zhang, Nan</au><au>Li, Yize</au><au>Zhu, Huayu</au><au>Ji, Qiuhe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer</atitle><jtitle>NPJ breast cancer</jtitle><stitle>npj Breast Cancer</stitle><date>2022-10-29</date><risdate>2022</risdate><volume>8</volume><issue>1</issue><spage>115</spage><epage>115</epage><pages>115-115</pages><artnum>115</artnum><issn>2374-4677</issn><eissn>2374-4677</eissn><abstract>Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy (trastuzumab), cancer stem cell (CSC)-like properties and multiple chemoresistance often concur and intersect in breast cancer, but molecular links that may serve as effective therapeutic targets remain largely unknown. Here, we identified the long noncoding RNA, LINC00589 as a key regulatory node for concurrent intervention of these processes in breast cancer cells in vitro and in vivo. We demonstrated that the expression of LINC00589 is clinically valuable as an independent prognostic factor for discriminating trastuzumab responders. Mechanistically, LINC00589 serves as a ceRNA platform that simultaneously sponges miR-100 and miR-452 and relieves their repression of tumor suppressors, including discs large homolog 5 ( DLG5 ) and PR/SET domain 16 ( PRDM16 , a transcription suppressor of mucin4 ), thereby exerting multiple cancer inhibitory functions and counteracting drug resistance. Collectively, our results disclose two LINC00589 -initiated ceRNA networks, the LINC00589 - miR-100 - DLG5 and LINC00589 - miR-452 - PRDM16 - mucin4 axes, which regulate trastuzumab resistance, CSC-like properties and multiple chemoresistance of breast cancer, thus providing potential diagnostic and prognostic markers and therapeutic targets for HER2-positive breast cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36309503</pmid><doi>10.1038/s41523-022-00484-0</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6137-2252</orcidid><orcidid>https://orcid.org/0000-0002-3038-6624</orcidid><orcidid>https://orcid.org/0000-0002-3010-5837</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2374-4677
ispartof NPJ breast cancer, 2022-10, Vol.8 (1), p.115-115, Article 115
issn 2374-4677
2374-4677
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cd232e58e9a24f2eb973d30f7c78ab61
source PubMed Central Free; Publicly Available Content Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/337/384
692/4028/67/1059/2326
692/53/2422
692/699/67/1347
Biomedical and Life Sciences
Biomedicine
Biopsy
Breast cancer
Cancer Research
Cell Biology
Cloning
Drug resistance
Epidermal growth factor
Human Genetics
Liver cancer
Lymphatic system
Medical prognosis
Medical research
Oncology
Patients
Proteins
Roles
Stem cells
title LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A31%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LINC00589-dominated%20ceRNA%20networks%20regulate%20multiple%20chemoresistance%20and%20cancer%20stem%20cell-like%20properties%20in%20HER2+%20breast%20cancer&rft.jtitle=NPJ%20breast%20cancer&rft.au=Bai,%20Wendong&rft.date=2022-10-29&rft.volume=8&rft.issue=1&rft.spage=115&rft.epage=115&rft.pages=115-115&rft.artnum=115&rft.issn=2374-4677&rft.eissn=2374-4677&rft_id=info:doi/10.1038/s41523-022-00484-0&rft_dat=%3Cproquest_doaj_%3E2730316926%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c517t-dd33015cbab2285171e43699e98bb1da21ab67b781cc54b702c4fb4b2111b073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2729999905&rft_id=info:pmid/36309503&rfr_iscdi=true